José Baselga, MD, the chief medical officer of Memorial Sloan Kettering Cancer Center, resigned after it was reported that he failed to disclose any industry ties in 60% of the nearly 180 papers he had published since 2013; an idea to give a push to the president’s plan to disclose drug prices on television was sunk this week by House Republicans; transgender adolescents attempt suicide at a much higher rate than young people whose gender identity matches the sex on their birth certificates.
José Baselga, MD, the chief medical officer of Memorial Sloan Kettering Cancer Center, resigned after ProPublica and The New York Times found that he failed to report any industry ties in 60% of the nearly 180 papers he had published since 2013. That figure increased each year. Last year, he did not disclose any relationships in 87% of the journal articles that he cowrote, according to the report.
An idea to give a push to the president’s plan to disclosed drug prices on television was sunk this week by House Republicans, STAT reported. Senator Dick Durbin, D-Illinois, and Senator Chuck Grassley, R-Iowa, wanted to include an amendment in a major government funding bill that would give the FDA $1 million to kick off advertising idea, which he first floated in May. But the amendment failed to make into a final version being hashed out in a Senate-House reconciliation meeting about the funding bills, aides and Congressman Tom Cole, R-Oklahoma, said.
Transgender adolescents attempt suicide at a much higher rate than young people whose gender identity matches the sex on their birth certificates, according to a new study published this week in Pediatrics. The Washington Post reported on the study, as well as the experience of 1 transgender woman whose experiences led her to create a hotline called Trans Lifeline. The highest rate reported in the study was suffered by transgender male adolescents (51%).
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen